ImmuPharma (LON:IMM) Share Price Passes Above 200 Day Moving Average – Should You Sell?

ImmuPharma plc (LON:IMMGet Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 5.43 and traded as high as GBX 9.70. ImmuPharma shares last traded at GBX 9.26, with a volume of 5,849,270 shares changing hands.

ImmuPharma Stock Up 9.3%

The company has a market capitalization of £50.88 million, a P/E ratio of -11.37 and a beta of 1.53. The business has a fifty day moving average price of GBX 10.98 and a 200 day moving average price of GBX 5.43.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.